FRI0230 Retention rates of tnf inhibitors and abatacept used as a first biologic dmard in the treatment of rheumatoid arthritis: 8 years of experience from the rhumadata® registry

MLA

M Mtibaa, et al. “FRI0230 Retention Rates of Tnf Inhibitors and Abatacept Used as a First Biologic Dmard in the Treatment of Rheumatoid Arthritis: 8 Years of Experience from the Rhumadata® Registry.” Poster Presentations, June 2017. EBSCOhost, https://doi.org/10.1136/annrheumdis-2017-eular.2326.

APA

M Mtibaa, E Muratti, J.-P. Pelletier, Frédéric Massicotte, J.-P. Raynauld, Roelien Postema, Boulos Haraoui, M-A Rémillard, Evo Alemao, L. Coupal, Louis Bessette, Έ. Villeneuve, D. Sauvageau, A Turcotte, & Denis Choquette. (2017). FRI0230 Retention rates of tnf inhibitors and abatacept used as a first biologic dmard in the treatment of rheumatoid arthritis: 8 years of experience from the rhumadata® registry. Poster Presentations. https://doi.org/10.1136/annrheumdis-2017-eular.2326

Chicago

M Mtibaa, E Muratti, J.-P. Pelletier, Frédéric Massicotte, J.-P. Raynauld, Roelien Postema, Boulos Haraoui, et al. 2017. “FRI0230 Retention Rates of Tnf Inhibitors and Abatacept Used as a First Biologic Dmard in the Treatment of Rheumatoid Arthritis: 8 Years of Experience from the Rhumadata® Registry.” Poster Presentations, June. doi:10.1136/annrheumdis-2017-eular.2326.